High-Flow Oxygen Reduces Intubation but Not Mortality in Acute Hypoxemic Respiratory Failure: NEJM
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2026-03-31 14:30 GMT | Update On 2026-03-31 14:30 GMT
France: Researchers have discovered in a large randomized trial (SOHO trial) that high-flow oxygen therapy did not improve survival compared to standard oxygen in patients with acute hypoxemic respiratory failure. However, it significantly reduced the need for intubation, indicating a clinical benefit as a secondary outcome.
Experts believe these results refine expectations, suggesting that while survival may not improve, early use of high-flow oxygen remains justified in suitable patients to potentially avoid invasive ventilation.
A recent study published in the New England Journal of Medicine by Jean-Pierre Frat and colleagues provides important insights into the role of oxygen delivery strategies in managing acute hypoxemic respiratory failure. The multicenter, open-label SOHO trial was designed to evaluate whether high-flow nasal oxygen could improve survival outcomes compared to standard oxygen therapy in critically ill patients.
The trial enrolled over 1,100 patients across multiple centers, all of whom met strict inclusion criteria, including significantly impaired oxygenation, elevated respiratory rates, and evidence of lung involvement on imaging. Participants were randomly assigned to receive either high-flow oxygen via nasal cannula or conventional oxygen therapy. The primary endpoint of the study was mortality at 28 days, while secondary outcomes included the need for intubation and safety measures.
The researchers reported the following findings:
- No difference in survival was observed between the two groups, with identical 28-day mortality rates of 14.6% in both high-flow oxygen and standard oxygen groups.
- Statistical analysis confirmed that high-flow oxygen did not provide any survival advantage over standard oxygen therapy.
- High-flow oxygen therapy was associated with a reduction in the need for intubation.
- Intubation was required in 42.4% of patients in the high-flow group compared to 48.4% in the standard oxygen group.
- The reduction in intubation rates was modest but statistically significant, suggesting a potential role in delaying or preventing invasive mechanical ventilation.
- Serious adverse events, including cardiac arrest and pneumothorax during spontaneous breathing, were slightly more frequent in the high-flow oxygen group.
- Despite this, the overall incidence of adverse events remained low.
- No new safety concerns were identified with the use of high-flow oxygen therapy.
The authors concluded that while high-flow oxygen therapy does not reduce short-term mortality in patients with acute hypoxemic respiratory failure, its ability to lower intubation rates supports its continued use in clinical practice. These findings highlight the importance of selecting appropriate endpoints when evaluating respiratory support strategies and suggest that avoiding invasive ventilation may itself be a meaningful clinical goal.
Overall, the study adds to the growing body of evidence guiding oxygen therapy in critical care, emphasizing a nuanced approach where benefits beyond survival, such as reduced intervention burden, are carefully considered.
Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2516087
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.